Thomas A. West - 31 Dec 2022 Form 5 Insider Report for Orthofix Medical Inc. (OFIX)

Reporting relationship: Director
Issuer ticker: OFIX
Reported as of: 31 Dec 2022
Net transaction value: +$6,989
SEC form: 5
Accepted by SEC: 11 Jan 2023, 15:54:38 UTC
Prior SEC filing: 08 Jun 2022
Next SEC filing: 04 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Kimberley Elting, President, Global Orthopedics, by power of attorney

Key filing fact

Thomas A. West filed Form 5 for Orthofix Medical Inc. (OFIX) on 11 Jan 2023.

Key facts

This page summarizes Thomas A. West's Form 5 filing for Orthofix Medical Inc. (OFIX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Jan 2023, 15:54.

Change

Previous filing in this sequence was filed on 08 Jun 2022.
Current net transaction value: +$6,989.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OFIX transaction

Common Stock

Award

Transaction value: $6,989
Shares: +512
Change %: +7.8%
Price: $13.65
Shares after: 7,055
Date: 31 Oct 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Thomas A. West is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Shares purchased pursuant to the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan, as Amended (the "Stock Purchase Plan") for the plan period ended October 31, 2022.

Footnote F2

Pursuant to the terms of the Stock Purchase Plan, shares are purchased at 85% of the fair market value of the Orthofix stock on the first day of the plan period or, if lower, on the last day of the plan period. Accordingly, shares were purchased at $13.65 per share, or at 85% of the quoted market price of $16.06 on October 31, 2022.